Lysis of a Broad Range of Epithelial Tumour Cells by Human γδ T Cells: Involvement of NKG2D ligands and T‐cell Receptor‐ versus NKG2D‐dependent Recognition
- 16 July 2007
- journal article
- research article
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 66 (2-3) , 320-328
- https://doi.org/10.1111/j.1365-3083.2007.01963.x
Abstract
Human gammadelta T cells expressing a V gamma 9V delta 2 T-cell receptor (TCR) kill various tumour cells including autologous tumours. In addition to TCR-dependent recognition, activation of NKG2D-positive gammadelta T cells by tumour cell-expressed NKG2D ligands can also trigger cytotoxic effector function. In this study, we investigated the involvement of TCR versus NKG2D in tumour cell recognition as a prerequisite to identify tumour types suitable for gammadelta T-cell-based immunotherapy. We have characterized epithelial tumour cells of different origin with respect to cell surface expression of the known NKG2D ligands MHC class I-chain-related antigens (MIC) A/B and UL16-binding proteins (ULBP), and susceptibility to gammadelta T-cell killing. Most tumour cells expressed comparable levels of MICA and MICB as well as ULBP with the exception of ULBP-1 which was absent or only weakly expressed. Most epithelial tumours were susceptible to allogeneic gammadelta T-cell lysis and in the case of an established ovarian carcinoma to autologous gammadelta T-cell killing. Lysis of resistant cells was enhanced by pre-treatment of tumour cells with aminobisphosphonates or pre-activation of gammadelta T cells with phosphoantigens. A potential involvement of TCR and/or NKG2D was investigated by antibody blockade. These experiments revealed three patterns of inhibition, i.e. preferential inhibition by anti-TCR antibody, preferential inhibition by anti-NKG2D antibody, or additive blockade by anti-TCR plus anti-NKG2D antibodies. Our results indicate for the first time that the NKG2D pathway is involved in the lysis of different melanomas, pancreatic adenocarcinomas, squamous cell carcinomas of the head and neck, and lung carcinoma.Keywords
This publication has 56 references indexed in Scilit:
- Activated γδ T cells express the natural cytotoxicity receptor natural killer p44 and show cytotoxic activity against myeloma cellsClinical and Experimental Immunology, 2006
- Release of MICB Molecules by Tumor Cells: Mechanism and Soluble MICB in Sera of Cancer PatientsHuman Immunology, 2006
- Combination Immunotherapy with Clinical-Scale Enriched Human γδ T cells, hu14.18 Antibody, and the Immunocytokine Fc-IL7 in Disseminated NeuroblastomaClinical Cancer Research, 2005
- γδ T cells: A new frontier for immunotherapy?Published by Elsevier ,2005
- Human ???? T Cells From G-CSF-Mobilized Donors Retain Strong Tumoricidal Activity and Produce Immunomodulatory Cytokines After Clinical-Scale IsolationJournal of Immunotherapy, 2005
- Potential of human γδ T lymphocytes for immunotherapy of cancerInternational Journal of Cancer, 2004
- Immunoregulation in the tissues by γδ T cellsNature Reviews Immunology, 2003
- MICA Engagement by Human Vγ2Vδ2 T Cells Enhances Their Antigen-Dependent Effector FunctionImmunity, 2001
- Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICAScience, 1999
- Functional analysis of TCR γδ+ T cells in tumour-infiltrating lymphocytes (TIL) of human pancreatic cancerClinical and Experimental Immunology, 1993